A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
PDS Biotechnology Corp.
Groupe Oncologie Radiotherapie Tete et Cou
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Brown University
Incyte Corporation
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
GlaxoSmithKline
GlaxoSmithKline